Bio-Gene Technology Ltd (ASX: BGT) Share Price and News

Price

$0.025

Movement

0.00 (0.0)

as at 28 Apr - Closed (20 mins delayed)

52 Week Range

$0.024 - $0.075

 
1 Year Return

-66.67%

Bio-Gene Technology Ltd Chart and Price Data

Fundamentals Data provided by Morningstar.

Data provided by Morningstar.
Market Cap $5.03 million
P/E Ratio N/A
Dividend Yield 0.00%
Shares Outstanding 201.36 million
Earnings per share -0.012
Dividend per share N/A
Year To Date Return -41.86%
Earnings Yield N/A
Franking -
Share Price

$0.025

Day Change

0.00 (0.0)

52 Week Range

$0.024 - $0.075

Yesterday's Close

$0.025

Today's Open

$0.025

Days Range

$0.025 - $0.025

Volume

1,267

Avg. Volume (1 month)

135,409

Turnover

$32

as at 28 Apr - Closed

Bio-Gene Technology Ltd (ASX: BGT)
Latest News

A little girl with red hair runs excitedly with a rocket strapped to her back, trying to launch.
Small Cap Shares

Guess which ASX small-cap stock exploded 154% on big US news!

ASX small-cap stocks carry added risk, but also sometimes offer supersized rewards.

Read more »

BGT ASX Announcements

An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.

DateAnnouncementPrice Sensitive?TimeNo. of PagesFile Size
20th Mar 2025 2025-03-20T09:29:14 Bio-Gene Presentation - NWR Virtual Healthcare ConferenceYesNo9:29am252.3M
17th Mar 2025 2025-03-17T08:20:28 BGT to present at virtual healthcareYesNo8:20am1140k
27th Feb 2025 2025-02-27T18:09:13 Appendix 4D and Half-Year Accounts 31 December 2024YesNo6:09pm20877k
4th Feb 2025 2025-02-04T10:28:57 BGT Investor Webinar 4-Feb-25 SlidesYesNo10:28am7585k
31st Jan 2025 2025-01-31T11:49:09 Investor Webinar Tue 4 Feb 2025YesNo11:49am1148k
30th Jan 2025 2025-01-30T08:24:32 Quarterly Activities/Appendix 4C Cash Flow ReportYesNo8:24am10452k
29th Jan 2025 2025-01-29T09:15:56 BGT Awarded U.S. Department of Defense GrantsYesNo9:15am4257k
2nd Dec 2024 2024-12-02T13:34:16 Notification of cessation of securities - BGTYesNo1:34pm413k
29th Nov 2024 2024-11-29T13:41:20 Results of MeetingYesNo1:41pm2553k
29th Nov 2024 2024-11-29T11:10:59 CEO's Address to ShareholdersYesNo11:10am6284k

About Bio-Gene Technology Ltd

Bio-Gene Technology Ltd is an Australian company developing novel bio-insecticides to address the challenges of insecticide resistance. Its products are Flavocide and Qcide which include a naturally occurring class of compounds to overcomeresistance to control pests with minimal impact on human health and the environment. The group's product has multiple applications across public health, crop protection, grain storage, and consumer use. It provides new options derived fromnature to meet market demand for effective and safe pest management solutions.

BGT Share Price History Data provided by Morningstar.

Data provided by Morningstar.
Date Close Change % Change Volume Open High Low
24 Apr 2025 $0.03 $0.00 0.00% 3,500 $0.03 $0.03 $0.03
23 Apr 2025 $0.03 $0.00 0.00% 9,252 $0.03 $0.03 $0.03
22 Apr 2025 $0.03 $0.00 0.00% 88,418 $0.03 $0.03 $0.03
17 Apr 2025 $0.03 $0.00 0.00% 672,565 $0.03 $0.03 $0.02
16 Apr 2025 $0.03 $0.00 0.00% 304,085 $0.03 $0.03 $0.03
10 Apr 2025 $0.03 $0.00 0.00% 455,849 $0.03 $0.03 $0.03
09 Apr 2025 $0.03 $0.00 0.00% 568,491 $0.03 $0.03 $0.03
07 Apr 2025 $0.03 $0.00 0.00% 70,608 $0.04 $0.04 $0.03
04 Apr 2025 $0.04 $0.00 0.00% 50 $0.04 $0.04 $0.04
02 Apr 2025 $0.04 $0.00 0.00% 16,855 $0.04 $0.04 $0.04
01 Apr 2025 $0.03 $0.00 0.00% 101,000 $0.03 $0.03 $0.03
31 Mar 2025 $0.03 $0.00 0.00% 146,687 $0.03 $0.03 $0.03

Directors & Management Data provided by Morningstar.

Data provided by Morningstar.
Name Title Start Date Profile
Mr Peter May Research & DevelopmentExecutive Director May 2015
Mr May career has included over 20 years of experience in the Australian and international crop protection and pest management markets with companies Orica and Crop Care (now part of Nufarm). In 2001, he founded Xavca Pty Ltd, providing marketing & consultancy services to mainly international clients including Syngenta and Sorex (now part of BASF).
Mr Andrew Wallace Guthrie Non-Executive Director Apr 2021
Mr Guthrie has committed his career to agriculture and worked for 32 years with one of the agriculture companies, Syngenta, and predecessor companies around the world. After building his early career in sales, marketing and supply chain roles in Australian agriculture, Andrew spent 20 years working internationally with assignments in the United Kingdom, Switzerland, Hong Kong, Singapore, Thailand, Japan and China. He gained experience in diverse cultural environments that require broad leadership skills. Andrew spent most of his senior leadership years with Syngenta in Asia, as Regional Director for Asia Pacific, before he was promoted to lead Syngenta's business in Europe, Africa and the Middle East. He is Chair of the Risk Committee.
Mr Alex Huong Soo Ding Non-Executive DirectorNon-Executive Chairman May 2023
Mr Ding has over 25 years of experience as a corporate lawyer. He was a partner at two Australian law firms and is skilled in mergers and acquisitions, capital markets, and general corporate and governance law. He has advised many ASX, LSE and US listed companies, foreign government-controlled entities and private companies and funds on acquisitions, divestments, corporate finance transactions, joint venture arrangements, restructurings, corporate governance and disputes strategy.M
Mr Christopher Mark Ramsey Non-Executive Director May 2023
Mr Ramsey has over 30 years of experience in the agricultural sector across business startup, development, marketing and broader agronomy. He has held leadership roles in Bayer, BASF and Nufarm/Crop Care among others, operating in both technical and managerial roles. Chris brings with him experience across customer engagement and product marketing and has a history of partnership development and sourcing after having spent the earlier years of his career in technical agricultural roles. Chris currently acts as non-executive director of Northwest Phosphate, a phosphate exploration and production business and RegenCo Natural Capital Specialists. He is member of the Risk Committee.
Mr Owen Timothy Grogan Chief Executive OfficerManaging Director Aug 2023
Mr Grogan brings more than 30 years of experience and expertise to Bio-Gene, with a track record of delivering growth in the agtech, food and human health sectors. Tim has multi-disciplinary experience in the management of new product development, commercialisation, capital raising and corporate governance.
Mr Edmond Tern Chief Financial OfficerCompany Secretary Apr 2024
-
Edmond Tern Chief Financial OfficerCompany Secretary
-

Top Shareholders Data provided by Morningstar.

Data provided by Morningstar.
Name Shares Capital
Citicorp Nominees Pty Limited 16,106,415 8.00%
Vana Belle Pty Ltd 11,761,904 5.80%
Dr Choon Huat Lee 9,558,233 4.70%
Mr James Vincent Chester 7,665,524 3.80%
T & L Ainsworth Investments 6,683,185 3.30%
Alina Barlow 5,952,381 3.00%
Invia Custodian Pty Limited 5,488,500 2.70%
Maclee Pty Ltd 3,650,000 1.80%
Richard Andrew Jagger 3,412,918 1.70%
P L Moran Pty Ltd 3,310,000 1.80%
Arision Pty Limited 2,955,265 1.50%
Magdajano Pty Ltd 2,885,000 1.40%
Bitola Pty Ltd 2,380,000 1.20%
Mr Anthony William Olding & 2,150,000 1.10%
BNP Paribas Nominees Pty Ltd 2,111,481 1.00%
Pyxis Holdings Pty Ltd 2,000,000 1.00%
Peter Donald May 1,842,205 0.90%
Mr Victor Rosenberg & 1,837,000 0.90%
Varasalv Pty Ltd 1,819,047 0.90%
Xeen Pty Ltd 1,618,797 0.80%

Profile

since

Note